[go: up one dir, main page]

WO2008022365A3 - Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions - Google Patents

Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions Download PDF

Info

Publication number
WO2008022365A3
WO2008022365A3 PCT/AT2007/000404 AT2007000404W WO2008022365A3 WO 2008022365 A3 WO2008022365 A3 WO 2008022365A3 AT 2007000404 W AT2007000404 W AT 2007000404W WO 2008022365 A3 WO2008022365 A3 WO 2008022365A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
galanthamine
analogues
derivatives
influencing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2007/000404
Other languages
German (de)
French (fr)
Other versions
WO2008022365A2 (en
Inventor
Werner Frantsits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanochemia Ltd
Original Assignee
Sanochemia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Ltd filed Critical Sanochemia Ltd
Publication of WO2008022365A2 publication Critical patent/WO2008022365A2/en
Anticipated expiration legal-status Critical
Publication of WO2008022365A3 publication Critical patent/WO2008022365A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of galanthamine of the formula (I) and derivatives or analogues of galanthamine for controlling the effect of toxic organic phosphorus compounds such as parathion, paraxon, sarin, soman or tabun is described, wherein a composition comprising the said compound or a combination of at least two of the said compounds is administered before and/or after contact of a human with the toxic organic phosphorus compound.
PCT/AT2007/000404 2006-08-24 2007-08-23 Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions Ceased WO2008022365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1417/2006 2006-08-24
AT14172006 2006-08-24

Publications (2)

Publication Number Publication Date
WO2008022365A2 WO2008022365A2 (en) 2008-02-28
WO2008022365A3 true WO2008022365A3 (en) 2009-04-09

Family

ID=39107152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2007/000404 Ceased WO2008022365A2 (en) 2006-08-24 2007-08-23 Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions

Country Status (1)

Country Link
WO (1) WO2008022365A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132135B2 (en) 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
RU2404160C1 (en) * 2009-06-01 2010-11-20 Федеральное государственное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации"(ФГУ "33 ЦНИИИ МО РФ") Use of n, n-diethylaniline as soman imitator in aqueous medium
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
CN104860955B (en) * 2015-04-22 2017-07-14 华东理工大学 Galantamine analogs and uses thereof
CN118908968B (en) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 A galanthamine intermediate derivative and a catalytic oxidation preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342174C1 (en) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermal therapeutic system and a method for producing a transdermal therapeutic system for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of poisoning by highly toxic organophosphorus neurotoxins, in particular Soman and its use
US20030199493A1 (en) * 2000-03-31 2003-10-23 Ulrich Jordis Novel derivatives and analogues of galanthamin
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
WO2005030332A2 (en) * 2003-09-29 2005-04-07 Sanochemia Pharmazeutika Ag Use of galanthamine and the derivatives thereof in the production of medicaments
WO2005030333A2 (en) * 2003-09-29 2005-04-07 Sanochemia Pharmazeutika Ag Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342174C1 (en) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermal therapeutic system and a method for producing a transdermal therapeutic system for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of poisoning by highly toxic organophosphorus neurotoxins, in particular Soman and its use
US20030199493A1 (en) * 2000-03-31 2003-10-23 Ulrich Jordis Novel derivatives and analogues of galanthamin
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
WO2005030332A2 (en) * 2003-09-29 2005-04-07 Sanochemia Pharmazeutika Ag Use of galanthamine and the derivatives thereof in the production of medicaments
WO2005030333A2 (en) * 2003-09-29 2005-04-07 Sanochemia Pharmazeutika Ag Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBUQUERQUE E X ET AL: "Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20060829 US, vol. 103, no. 35, 16 August 2006 (2006-08-16), pages 13220 - 13225, XP002513372, ISSN: 0027-8424 *
TONKOPII V D: "Oxidative stress in the mechanism of organophosphates neurotoxicity", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 144, no. Suppl, 1 September 2003 (2003-09-01), pages s132, XP009109279, ISSN: 0378-4274 *

Also Published As

Publication number Publication date
WO2008022365A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008022365A3 (en) Compositions for influencing the effects of organophosphorus compounds and use of galanthamine, its derivatives and analogues for producing such compositions
WO2008067119A3 (en) Novel compounds
PT2038290E (en) Modulators of toll-like receptor 7
GT200900154A (en) DERIVATIVES OF 2,3-DIHYDROIMIDOZO [1,2-C] QUINIZOLINA SUBSTITUTED FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008108491A1 (en) Pest control composition
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EP1834637A4 (en) Preventive/therapeutic composition for free radical disease
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
PT2040755E (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
TW200833254A (en) Composition for preventing and eliminating noxious parasite of tree
EP1712245A3 (en) Calcium phosphate cement
UA94606C2 (en) 2-thioxanthine derivatives, composition containing the compound and the use thereof in therapy
WO2008048589A3 (en) Compounds and methods for treatment of hcv
WO2009141548A3 (en) Composition and process for the destruction of organophosphorus and/or organosulphur pollutants
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2007130821A3 (en) Mglur5 modulators ii
MX2008011576A (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs.
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
TW200613279A (en) New pesticides
WO2007115287A3 (en) Combination of organic compounds
WO2008073195A3 (en) Method for activation of oxazaphosphorines
WO2008098077A3 (en) Substituted alkine derivatives as anti-cancer agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784631

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07784631

Country of ref document: EP

Kind code of ref document: A2